Claudia Adams Barr Program

Claudia Adams Barr

Claudia Adams Barr 1910-1957

The Claudia Adams Barr Program in Innovative Basic Cancer Research supports new lines of research, playing an essential role in the development of early-career scientists who work on a broad range of research investigations that yield new clues about cancer. The Barr Program funds their most innovative ideas to proper basic research discovered that transform cancer treatment. Program investigator have made tremendous advances and spearheaded breakthroughs that are improving survival for patients everywhere.

It's All About Impact

Major discoveries icon

Major Discoveries

Cancer research funding icon

Research Funding

Awards icon

Prestigious Awards

High-profiles papers icon

High-Profile Papers

Make a donation to support this innovative work.

Program Advancements

DFMC Runners, visit your Participant Center for additional Barr Program project summaries to share with your supporters.

Blood Cancer Barr Program Impact Statements

Blood Cancers

Finding New Therapeutic Targets for Blood Cancers

James Griffin, MD, uncovered evidence that a protein, BRD7, plays a critical role in the development of blood cancers, including acute myeloid leukemia (AML), an aggressive leukemia. His team is targeting BRD7 with small molecules as prototypes for leukemia therapies and investigating how BRD7 promotes leukemia cell survival during blood development.

Brain Cancer Barr Program Impact Statements

Brain Cancers

New Treatment Opportunities

Rosalind Segal, MD, PhD, parlayed her funding into the discovery that a genetic pathway called “Notch” is consistently damaged in brain tumors. Drugs already existed for other diseases to target Notch, and clinical trials are now exploring opportunities to use these drugs to improve survival for patients with brain cancer.

Breast Cancer Barr Program Impact Statements

Breast Cancers

New Function for BRCA1

Elodie Hatchi’s, PhD, research shed new light on one way that the BRCA1 gene functions at a molecular level. Dr. Hatchi’s unprecedented work is the first to identify and outline the relationship between BRCA1 and unusual DNA structures, and the role this interaction may play in forming breast cancer cells.

Cancer Biology Barr Program Impact Statements

Cancer Biology

Unlocking the Mysteries of Genomic Rearrangements

Cheng-Zong Zhang, PhD, is exploring whether breakage-fusion-bridge (BFB)-induced genetic rearrangements are more likely to occur at DNA sites undergoing transcription, how they affect transcription, and the impact this has on cellular behaviors. This may lead to clues about cancer development, achieving better prevention strategies and combatting drug-resistant tumors.

Cancer Genetics Barr Program Impact Statements

Cancer Genetics

Uncovering New Links Between Metabolism and Cancer

Edward Chouchani, PhD, has uncovered that accumulated lactate interacts with and modifies the activities of specific proteins influencing cancer cell growth and proliferation. He is working with colleagues to uncover the molecular basis for lactate’s protein interactions and to identify other key proteins that lactate targets to influence cancer cell activities.

Immunotherapy Barr Program Impact Statements

Immunotherapies

New Ways to Activate the Immune System

Glenn Dranoff, MD, discovered complex regulatory pathways in the immune system that cancers exploit to escape destruction. Reversal of these effects can lead to the development of vaccines against cancer, like Provenge for prostate cancer, and has enabled development of immune-activating drugs such as ipilimumab, which is approved by the FDA for metastatic melanoma.

Lung Cancer Barr Program Impact Statements

Lung Cancer

Targeting KRAS in Lung and Colorectal Tumors

Fay Nicolson, PhD, is developing non-invasive strategies for detecting and treating KRAS G12C-driven lung tumors using two radioactive agents. The first is used during a PET scan to visualize tumors with the mutation; the second delivers toxic radiation directly to mutant tumor cells while leaving normal cells unharmed.

Ovarian Cancer Barr Program Impact Statements

Ovarian Cancer

Leveraging the Immune System to Fight Ovarian Cancer

Han Dong, PhD, identified a cellular communication network helping memory-like natural killer cells grow and survive longer. She is testing if manipulating this network encourages these cells to attack and eliminate ovarian tumors and whether cancer-fighting activity can be boosted through small molecules helping to retain their anti-cancer properties in the microenvironment.

Pancreatic Cancer Barr Program Impact Statements

Pancreatic Cancer

Modeling Pancreatic Cancers to Fuel Discovery

Srivatsan Raghavan, MD, PhD, is generating mouse models for basal and classical pancreatic cancers to identify drugs that work selectively against each subtype. He is also looking for molecular signals in tumor environments that cause one type to switch to the other, which could lead to new therapeutic targets for this hard-to-treat disease.

Pediatric Cancer Barr Program Impact Statements

Pediatric Cancers

Finding New Weaknesses in Pediatric Brain Tumors

Volker Hovestadt, PhD, studies pediatric brain tumors forming during early-stage brain development before a child is born. He is using stem cells to generate “mini-brains” and manipulating their molecular properties to induce tumor formation, with the goal of learning how embryonic brain tumors develop and identifying vulnerabilities within them to target.

Precision Medicine Barr Program Impact Statements

Precision Medicine

Determining When to Use Chemotherapy

Anthony Letai, MD, PhD, developed a powerful test determining whether a patient's cancer cells will be destroyed by chemotherapy, which enables physicians to select the most appropriate treatment. Dr. Letai is now confirming the efficacy of this test, with the goal of making it available for a range of different cancer types.

Prevention Barr Program Impact Statements

Prevention

Developing a Cancer Prevention Drug

Bruce Spiegelman, PhD, is using mass spectrometry to test metformin—a type 2 diabetes drug that has shown cancer prevention potential—against thousands of proteins to identify which will bind to the drug. Should a target protein be validated, he aims to partner with chemists to develop a more potent form of metformin.